Quoin stock rises after expanding distribution deal with ER-Kim for QRX003

ilkercelik/E+ via Getty Images

• Quoin Pharmaceuticals (QNRX +0.9%) extended its exclusive distribution agreement with ER-Kim to six additional countries for QRX003, to treat Netherton Syndrome.
• Under the terms of the revenue sharing agreement, which was initially announced in February, ER-Kim (a partner for biotech companies in Central and Eastern Europe) gained exclusive rights to commercialize QRX003 in Turkey, Georgia, Azerbaijan, Greece, Cyprus, and Malta.
• The six countries and are in addition to the 15 countries covered under the initial agreement.
• "Quoin now has 60 countries under partnership distribution agreements for QRX003, which has the potential to become the first approved treatment for Netherton Syndrome," said Quoin CEO Michael Myers.
• Netherton syndrome is a rare hereditary disease characterized by scaling skin, hair anomalies and increased susceptibility to eczema, among other things.